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Abstract: Despite modern therapies with tyrosine kinase inhibitors (TKI), the management of patients with meta-
static renal cell carcinoma (mRCC) remains a challenge. Significant immunosuppression has been described in 
patients with mRCC. Therefore, immunotherapeutic strategies such as checkpoint inhibitors have been developed. 
To further elucidate the underlying mechanisms of immunosuppression and response to therapy, different features 
of the immune microenvironment (expression of HIF-1-α, VEGFR-1, FOXP3, TGF-ß1, CD80, CD86, PD-1, and PD-L1) 
were analyzed in tumor tissues within different subgroups of mRCC patients (responders vs. non-responders to 
therapy). Results: The most interesting finding was low-level CD80 and CD86-expression on tumor tissue samples (n 
= 18) of nearly all mRCC patients. This finding was in line with CD86 expression, which could also be found in renal 
carcinoma cell lines. To the best of our knowledge, this is the first report on CD80/CD86 expression in human renal 
cell carcinoma-possibly reflecting an immunomodulatory mechanism of the tumor. 
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Introduction
Over the last decade, potent targeted therapies 
have evolved for patients with mRCC [1-6]. 
Sequential use of these agents has led to an 
improvement in progression-free survival and 
(partially) overall survival as compared to cyto-
kine therapy [7-9]. However, despite the suc-
cessful development of novel targeted thera-
pies, the management of patients with mRCC 
remains challenging and relevant subgroups of 
patients are refractory to TKI treatment [10, 
11]. Recently, immune checkpoint pathways 
have been increasingly recognized and their 
inhibition has been incorporated into the treat-
ment strategies of several tumors, including 
mRCC [12-15]. Immune checkpoints pose an 
important immune evasion mechanism utilized 
by cancer cells. Cytotoxic T-lymphocyte-associa- 
ted protein 4 (CTLA-4) and programmed death 
1 (PD-1) protein are the key receptors on T cells 
mediating inhibitory interactions [16]. CTLA-4 is 
solely expressed on T cells and its inhibition 
leads to enhanced T cell activation via increased 
co-stimulation by CD28 [14, 16-19]. PD-1 is an 
immune-checkpoint receptor mediating immu-
nosuppression and is expressed by activated 
and follicular T cells, B cells, and NK-cells [20]. 
In tumors, these activated T cells may bind to 
their immunosuppressive ligands PD-L1 and 
PD-L2 [14], that are expressed by tumor cells 
and in the tumor microenvironment. PD-L1 may 
also be expressed on macrophages, myeloid-
derived suppressor cells (MDSC), dendritic cells 
(DC), B and T cells [21, 22]. It has recently been 
shown, that blockade of PD-1 or PD-L1 has sig-
nificant antitumor effects in RCC [12, 15, 23]. 
Multiple efforts have been made to correlate 
the expression of PD-L1 in tumor tissue with 
the clinical response to anti-PD-1 directed ther-
apy [12, 13, 24, 25]. So far, no clear relation-
ship could be established. However, the rele-
CD80 and CD86 expression in RCC
1444 Int J Clin Exp Pathol 2017;10(2):1443-1454
Table 1. Patients’ characteristics
Patient Age in years Histologic subtype Manifestations Therapy
PFS in 
weeks
1) CR after TKI therapy
    1 55 Clear cell Adrenal, Bone Sunitinib 106
    2 74 Clear cell Pulmonary Sunitinib 308
    3 62 Clear cell Pulmonary Sorafenib 472
    4 63 Clear cell Pulmonary, Bone Sunitinib 100
    5 69 Clear cell Pulmonary Sunitinib 60
    6 64 Clear cell Pulmonary, Lymphogenic Sunitinib 316
2) Aggressive disease/refractory to therapy
    1 41 Sarcomatoid/chromophob Pulmonary, hepatic None 8
    2 54 Clear cell Bone Sorafenib 5
    3 61 Sarcomatoid Pulmonary, hepatic, lymphogenic Temsirolimus 12
3) Cytokine treatment
    1 58 Clear cell Pulmonary, Lymphogenic Cytokines 33*
    2 40 Papillary Pulmonary, Adrenal, Spleen, Muscle, Local recurrence Cytokines 4*
    3 59 Not classified Bone, Adrenal, Lymphogenic Cytokines 30*
    4 59 Clear cell Pulmonary, Bone Cytokines 109
    5 62 Chromophob Pulmonary, Lymphogenic Cytokines 23
    6 60 Clear cell Pulmonary Cytokines 79 
    7 47 Clear cell Pulmonary Cytokines 23
Patients (n = 16) included the following subgroups: 1) Complete remission (CR) after tyrosine kinase inhibitor (TKI) therapy: n = 6. 2) Aggressive disease/refractory to therapy: n = 3. 
3) Cytokine treatment (IL-2/IFN-α/5-FU/GM-CSF): n = 7. *lost to follow-up after the weeks stated.
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vance of PD-L1 expression of tumor infiltrating 
lymphocytes remains interesting, particularly in 
the context of other immunomodulatory factors 
in the tumor microenvironment [16, 24]. Inte- 
restingly, in mRCC PD-L1 expression on tumor 
cells and lymphocytes has been more clearly 
correlated with an adverse outcome [26-31]. To 
further elucidate the underlying mechanisms of 
immunosuppression and response to therapy, 
we analyzed the expression of immunomodula-
tory molecules on tumor tissue samples within 
different subgroups of mRCC patients: patients 
with aggressive or TKI-refractory disease, pa- 
tients with TKI-responsive disease, and pa- 
tients treated with cytokines, in whom a nega-
tive correlation between CD80/CD86 expres-
sion on T cells and prognosis had previously 
been described [32]. Different molecules asso-
ciated with tumor cell proliferation (VEGFR-1, 
HIF-1-α) or immunomodulatory functions (CD- 
80, CD86, PD-1, PD-L1, TGF-ß1, and FOXP3) 
[14, 33] were included in our histological 
analyses. 
Material and methods
Patients
In our retrospective analysis, tissue samples (n 
= 18) from different subgroups of mRCC pa- 
tients (n = 16) were included: 6 patients had 
been highly responsive to TKI therapy (com-
plete remission under TKI therapy +/- metasta-
sectomy), 3 patients had been refractory to 
TKI-therapy, and 7 patients had been treated 
with cytokines [32]. Clinical information as well 
as follow-up reports were obtained through 
medical record review. The following parame-
ters were evaluated: histological subtype of the 
tumor, age at study entry, tumor manifesta-
tions, therapy regimen and time of progression-
free survival (see Table 1). The study was per-
formed in accordance with local ethical 
guidelines.
Immunohistological analysis
Immunohistological analyses were performed 
on 18 tumor tissue samples of 16 mRCC 
patients. Samples included nephrectomy sam-
ples (n = 13) and metastasectomy samples (n 
= 5). Four-micrometer-thick sections from par-
affin-embedded samples were performed for 
immunohistological staining. The following anti-
bodies were used:
The mouse monoclonal antibody against PD-1 
(clone MRQ-22), (Zytomed Systems GmbH, 
Berlin, Germany) was used in a dilution of 1:50. 
The antibodies against PD-L1, FOXP3, HIF-1- 
alpha, TGF-beta 1, CD80 and CD86 were pur-
chased from Abcam (Abcam plc 330 Cambridge, 
UK). For PD-L1 detection, a rabbit monoclonal 
antibody was used in a dilution of 1:300 (clone 
EPR1161 (2), FOXP3 (clone 236A/E7) was cho-
sen in a dilution of 1:100, HIF-1-alpha (mouse 
monoclonal antibody clone H1alpha67) in a 
dilution of 1:100, CD80 (clone EP1155Y) in a 
dilution of 1:2000, and CD86 (clone EP1158Y) 
in a dilution of 1:50. VEGFR-1 (polyclonal) was 
used in a dilution of 1:50 from Acris Antibodies 
(Acris Antibodies GmbH, Herford, Germany). All 
these stains were performed using the Bond- 
MaxTM device (Leica Biosystems GmbH, Wet- 
zlar, Germany). Antigen retrieval and visualiza-
tion of bound antibodies were performed 
employing the manufacturer’s protocols and 
reagents (Bond Polymer Refine, DAB; Leica). 
The sections were dewaxed and subjected to 
an antigen retrieval protocol within a BenchMark 
Ultra (Ventana) followed by incubation with the 
primary antibody. Bound antibodies were visu-
alized using the streptavidin-biotin-peroxidase 
method and diaminobenzidine as chromogen 
(UltraviewKit, also obtained from Ventana). The 
expression level was quantified as follows: (-) = 
Negative/single cells, (+) ≤ 25% expression, 
(++) = 25-50% expression, (+++) ≥ 50% expres-
sion, (n.a.) = not available. 
Flow cytometric analyses
For FACS analysis, fluorochrome-labeled anti-
bodies against CD80, CD86, and isotype con-
trols (all BD Biosciences, Heidelberg, Germany) 
were used according to the manufacturer’s 
instructions. 60.000 cells were analyzed on a 
BD FACSCanto using BDFACSDiva software, 
(BD Biosciences). Analysis was performed 
using Flow Jo software version 10 (FLOWJO 
LLC, Asland, OR, USA). Flow cytometric analy-
ses were performed on two renal carcinoma 
cell lines (CAKI1-HTB46 and CAKI2-HTB47), 
(ATCC/LGC Standards, Wesel, Germany).
Results
Expression of immunomodulatory molecules 
on renal cell carcinoma 
Low-level expression of CD80 was shown in 
89% (16/18) of tumor tissue samples (n = 18) 
CD80 and CD86 expression in RCC
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of mRCC patients. CD80 was expressed in the 
cytoplasm as well as on the cell membrane of 
the tumor cells (Figure 1A, 1B). Tumor infiltrat-
ing lymphocytes only scarcely expressed CD80 
(Figure 1C, 1D). CD86 expression could also be 
demonstrated in 89% (16/18) of patients’ 
tumor tissue samples. For CD86, both cyto-
plasmic and membranous expression could be 
observed in the tumor cells. Tumor infiltrating 
lymphocytes were mostly negative (Figure 1E). 
In the different subgroups of mRCC patients, no 
significant differences were observed concern-
ing CD86 or CD80 expression (Table 2). 
To support the finding of CD80/CD86 expres-
sion on RCC, additional flow cytometric analy-
ses were performed with renal carcinoma cell 
lines (CAKI1-HTB46 and CAKI2-HTB47). Low-
level CD86 expression could be demonstrated 
on both cell lines, whereas CD80 was negative 
(Figure 2). Furthermore, PD-L1 expression was 
analyzed on the available tumor tissue samples 
within the different subgroups. Interestingly, 
67% (2/3) of patients refractory to TKI-therapy 
showed PD-L1 expression on their tumors. In 
contrast, in the group of TKI-responsive 
patients, PD-L1 expression was only found in 
Figure 1. CD80 and CD86 expression on tumor tissue 
samples from patients with mRCC. (A and B) CD80 
(magnification ×20): CD80 expression is found in a 
substantial proportion of tumor cells, mainly on the 
membrane, but also in the cytoplasm of some tumor 
cells. Lymphocytes are mostly negative, only in some 
localizations (C) a portion of lymphocytes show a weak 
CD80 expression (magnification ×20). (D) (magnifica-
tion ×40): Negative control. (E) CD86 (magnification 
×20): Membranous and cytoplasmic expression of 
CD86 on tumor cells. Most of the lymphocytes are 
negative.
CD80 and CD86 expression in RCC
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Table 2. Expression of PD-1 and PD-L1 on samples of different subgroups of mRCC patients 
Patient CD86 CD80 PD-L1 PD-1
Tumor Tumor Tumor Lymphocytes Tumor Lymphocytes
CR after TKI therapy
    1 + ++ - - - -
    2 +++ ++ - + - -
    3 n.a. ++ n.a. n.a. n.a. n.a.
    4-1 ++ ++ - - - -
    4-2 +++ ++ - - - -
    4-3 +++ + - - - -
    5 + + - - n.a. -
    6 +++ ++ - - - -
Aggressive disease/refractory to therapy
    1 ++ + + - - -
    2 ++ - - - - -
    3 ++ + + - - -
Cytokine treatment
    1 - ++ - - - -
    2 + + - - - +
    3 - - - - - -
    4 ++ + - - - +
    5 ++ + - - - -
    6 ++ ++ - - - -
    7 ++ ++ - - - -
Expression of immunomodulatory markers was observed in tissue samples of different subgroups of mRCC patients and was 
quantified as follows: (-) = Negative / single cells, (+) ≤ 25% expression, (++) = 25-50% expression, (+++) ≥ 50% expression, 
(n.a.) = not available. The group contains three samples from one patient (patient 4). PD-1 = programmed cell death protein 1, 
PD-L1 = programmed death protein ligand 1.
Figure 2. CD86 and CD80 expression on renal carcinoma cell lines. Flow cytometric analyses demonstrated weak 
CD86 expression on both RCC cell lines, whereas CD80 is not expressed (RCC cell line 1 = CAKI1-HTB46 and RCC 
cell line 2 = CAKI2-HTB47). (__) = CD86, (….) = CD80, (■) = Isotype control.
CD80 and CD86 expression in RCC
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12.5% (1/8 samples) (Table 2). In our cohort of 
patients, only scarce lymphocyte infiltrations 
could be demonstrated in tumor tissue. There- 
fore, no significant PD-1 expression could be 
observed on tumor-infiltrating lymphocytes 
(TIL) in the different subgroups (n = 18). 
Since molecules influencing tumor growth or 
immunological responses may be expressed 
both on tumor cells themselves and in the 
tumor microenvironment, we have also studied 
the expression of different other molecules 
that are associated with tumor progression 
and/or immunological tolerance. TGF-ß1 was 
only weakly expressed on tumor cells in sam-
ples of TKI-responsive patients (62.5% = 5 of 8 
samples with expression on < 25% of tumor 
cells), whereas the expression level was mark-
edly higher in patients refractory to therapy 
(67% = 2 of 3 cases with expression on 25-50% 
of tumor cells, 33% = 1 of 3 cases with expres-
sion on > 50% of tumor cells) (Figures 3A and 
4A). The same distribution was observed for 
FOXP3: TKI-responsive patients showed only 
weak expression (in 100% = 8 of 8 cases with 
expression in only single lymphocytes or nega-
tive expression pattern), whereas higher 
expression could be observed in TKI-refractory 
patients (33% = 1 of 3 cases with expression 
on 25-50% of lymphocytes, 67% = 2 of 3 cases 
with expression in only a few cells) (Figure 4B). 
Surprisingly, a different pattern was observed 
for HIF-1-α on tumor cells: in TKI-responsive 
patients, a higher expression was found (62.5% 
= 3 of 8 cases with expression on > 50% of 
tumor cells, 12.5% = 1 of 8 cases with expres-
sion on 25-50% of tumor cells, 25% = 2 of 8 
cases with expression on < 25% of tumor cells).
In contrast, TKI-refractory patients showed a 
lower expression (100% = 3 of 3 cases with 
expression on only a few tumor cells or nega-
tive expression pattern) (Figure 4C). The expres-
sion pattern for VEGFR-1 was not substantially 
different: in TKI-responsive patients only a 
weak expression was found (62.5% = 5 of 8 
cases with expression on some tumor cells or 
negative expression, 25% = 2 of 8 cases with 
expression on < 25% of tumor cells, and 12.5% 
= 1 of 8 cases expression on 25-50% of tumor 
cells). TKI-refractory patients also showed 
weak expression (100% = 3 of 3 cases with 
expression on < 25% of tumor cells (Figures 3B 
and 4D).
Discussion
In patients with mRCC, targeted therapies have 
led to improvement in progression-free survival 
and (partially) overall survival. These therapies 
mainly mediate tumor cell death, however, mul-
tiple additional immunomodulatory mecha-
nisms have been described in RCC [34-40]. To 
further identify the underlying mechanisms of 
tumor-induced immune suppression and its 
correlation with response to therapy, we exam-
ined the expression pattern of molecules that 
Figure 3. Expression of immunomodulatory markers on samples of different subgroups of mRCC patients. A: TGF-
ß1 (magnification ×10): TGF-ß1 is mostly expressed in the cytoplasm of the tumor cells but also a membranous 
staining could be observed (arrow). B: VEGFR-1 (magnification ×10): Weak cytoplasmic expression of VEGFR-1 was 
observed in a portion of tumor cells. TGF-ß1 = transforming growth factor beta 1, VEGFR-1 = vascular endothelial 
growth factor receptor 1. 
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have been implicated in both tumor progres-
sion and immune responses in tumor tissue of 
patients with mRCC. 
HIF-1-α expression was particularly found in the 
subgroup of patients responding to TKI therapy. 
HIF-1-α is a driver of several pathways associ-
ated with disease progression in RCC [41]. 
Since some to these pathways are targeted by 
TKI therapy, it could be hypothesized that high 
HIF-1-α expression is predictive for response to 
TKI therapy. However, this issue remains con-
troversial, since no correlation between HIF-1-α 
expression and response to VEGF-directed tar-
geted therapies has been established so far 
[41, 42]. 
The most interesting finding was that CD86 
and CD80 are expressed in mRCC. CD80/86 
expression could be demonstrated throughout 
the different subgroups of mRCC patients, how-
ever, no clear correlation with clinical outcome 
could be established. This finding was support-
ed by CD86 expression on RCC tumor cell lines, 
which could be detected by flow cytometry. 
PD-L1 expression was associated with aggres-
sive/refractory disease. This is in line with pre-
vious reports describing a correlation between 
PD-L1 expression and an adverse outcome 
[26-30]. Additionally, further immunosuppres-
sive molecules such as TGF-ß1 and FOXP3 
were predominantly found in patients with 
aggressive/refractory disease. Since CD80/
CD86 expression was repetitively demonstrat-
ed on tumor samples within different sub-
groups of mRCC patients and- in the case of 
CD86- also on renal carcinoma cell lines, we 
Figure 4. Expression of immunomodulatory markers on samples of different subgroups of mRCC patients. Expres-
sion of immunomodulatory markers was observed in tissue samples of different subgroups of mRCC patients and 
was quantified as seen above. Expression in tumor infiltrating lymphocytes (TIL): FOXP3 = forkhead box P3, Expres-
sion in tumor cells: HIF-1-α = hypoxia inducible factor 1-alpha, TGF-ß1 = transforming growth factor beta 1, VEGFR-1 
= vascular endothelial growth factor receptor 1.
CD80 and CD86 expression in RCC
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can exclude technical artifacts leading to non-
specific staining.
In the literature, CD80 and CD86 expression 
have been described on both tumor cells and 
tumor infiltrating lymphocytes (TIL). 
In nasopharyngeal carcinoma [43], CD80 and 
CD86 expression was associated with improved 
clinical outcome [44]. In contrast, CD86 expres-
sion on myeloma cells and acute myeloid leuke-
mia has been linked to an adverse prognosis 
[45-47]. Expression on melanoma cells could 
not be correlated with clinical outcome [48, 
49]. Additionally, expression of CD80 in various 
murine cancer cell lines has previously been 
demonstrated [50]. To the best of our knowl-
edge, this is the first report demonstrating 
expression of CD80 and CD86 in human renal 
cell cancer. 
Additionally, there are reports on CD80-ex- 
pressing TIL in renal cell carcinoma. It has been 
hypothesized that these CD80+ TIL pose an 
example of self-co-stimulation between T cells, 
which may finally lead to unresponsiveness 
[51]. Furthermore, there are conflicting results 
on the relevance and prognostic significance of 
TIL in RCC [52]. Some recent observations 
demonstrate that TIL in RCC have very hetero-
geneous profiles with regard to the expression 
of immune checkpoint molecules and the pres-
ence of mature DC within the tumor, leading to 
a different clinical outcome [52, 53]. It has 
been reported that particularly tumor infiltra-
tion with CD8+ T cells expressing high levels of 
PD-1 in the absence of mature DC may lead to 
immunosuppression [53]. Ultimately, we have 
previously reported on CD80/CD86+ T cells 
in peripheral blood of renal cell carcinoma 
patients under cytokine therapy. These CD80/
CD86+ T cells were associated with an adverse 
outcome, possibly reflecting an inhibitory func-
tion. These different studies show that CD80/
CD86 expression may mediate different immu-
nological functions, depending on the immuno-
logical environment [32].
Thus, it seems very likely that the functional 
consequences of CD80 and CD86 expression 
on different cell types are not clear-cut with 
respect to stimulation or inhibition. It seems 
much more reasonable that they rather depend 
on the particular immunological context. 
Therefore, CD80/86 expression on RCC cells 
might balance both stimulatory and inhibitory 
signals, e.g. via CTLA-4 and CD28 on T cells.
Interestingly, expression of CD80 and PD-L1 on 
T cells has recently been linked and it has been 
shown that they may lead to impaired T cell pro-
liferation and decreased cytokine production. It 
has also been suggested, that CD80 may have 
a higher affinity for PD-L1 than for CD28, result-
ing in a predominantly inhibitory signal in the 
presence of PD-L1 [54]. Furthermore, tumor-
infiltrating immune effector cells selectively 
expressing CTLA-4 (and not CD28) have been 
observed [55] and CTLA-4+ T cells have been 
described particularly in undifferentiated RCC 
with an adverse prognosis [56]. Thus, CD80/86 
expression on the tumor might- at the same 
time-prevent T cell activation via CTLA-4 and 
inhibit effector T cells via PD-L1 interaction 
[14]. This may even occur in T cells, that express 
both CTLA-4 and CD28 since the binding affini-
ty of CD80/CD86 for CTLA-4 is higher than for 
CD28 [57, 58], with CD80 being the dominant 
CTLA-4-ligand and CD86 the dominant ligand 
of CD28 [59]. Therefore, it seems reasonable 
that expression of CD80 on RCC cells is a 
mechanism to prevent T cell activation within 
the tumor. These immunosuppressive interac-
tions via CD80/CD86-CTLA-4 and CD80-PD-L1 
might outweigh immunostimulatory interac-
tions via CD80/CD86-CD28. CD86 expression 
on tumor cells is an additional mechanism con-
tributing to immune evasion since CD86 may 
lead to proliferation and homeostasis of Treg 
[60]. Additionally, it has been shown that co-
stimulation via CD86 results in a TH2-
polarization of T cells with predominant secre-
tion of IL-4 and IL-10 which inhibit cytotoxic 
lymphocyte (CTL) responses [61, 62].
Interestingly, low-level CD80-expression was 
also observed in a murine colon carcinoma 
mouse model. In this mouse tumor model, low-
level CD80 expression- in contrast to high-level 
CD80-expression- was associated with immune 
escape due to high affinity binding to CTLA-4 
[50]. Therefore, the expression level of CD80/
CD86 within the tumor might be a further deter-
minant of immunological outcome.
In summary, we have demonstrated CD80 and 
CD86 expression in human renal cell carcino-
ma. In the context of recent literature, it seems 
very likely that these molecules are part of a 
network that may protect the tumor from being 
CD80 and CD86 expression in RCC
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attacked by T cells. It was beyond the scope of 
this study to unravel the exact mechanism, 
however, and to the best of our knowledge, this 
is the first report demonstrating CD80 and 
CD86 expression inhuman renal cell cancer. 
Our finding might be relevant for future immu-
notherapeutic strategies. 
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